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Hyperhomocysteinemia is a risk factor for obstructive
large-vessel disease. Here, we studied plasma concen-
trations of homocysteine and vitamins in patients suf-
fering from subcortical vascular encephalopathy (SVE),
a cerebral small-vessel disease leading to dementia.
These results were compared to the homocysteine and
vitamin plasma concentrations from patients with cere-
bral large vessel disease and healthy control subjects.
Plasma concentrations of homocysteine, vascular
risk factors and vitamin status (B6, B12, folate) were de-
termined in 82 patients with subcortical vascular en-
cephalopathy, in 144 patients with cerebral large-ves-
sel disease and in 102 control subjects. Patients with
SVE, but not those with cerebral large-vessel disease,
exhibited pathologically increased homocysteine con-
centrations in comparison with control subjects with-
out cerebrovascular disease. Patients with SVE also
showed lower vitamin B6 values in comparison to sub-
jects without cerebrovascular disease. Logistic regres-
sion analysis showed that homocysteine is associated
with the highest risk for SVE (odds ratio 5.7; CI
2.5–12.9) in comparison to other vascular risk factors
such as hypertension, age and smoking.
These observations indicate that hyperhomocys-
teinemia is a strong independent risk factor for SVE.
Key words: Homocysteine; Vitamin B6; Vitamin B12;
Cerebrovascular disease; Subcortical vascular en-
cephalopathy; Dementia.
Abbrevations: CI, confidence interval; CT, computed to-
mography; MRT, magnetic resonance tomography;
SVE, subcortical vascular encephalopathy.
Introduction
Dementia caused by cerebrovascular disease is the sec-
ond most frequent cause of dementia in older people af-
ter Alzheimer’s disease. A subtype of vascular dementia,
subcortical vascular encephalopathy (SVE) is character-
ized by progressive memory deficits and cognitive de-
cline, typical gait disorders, and incontinence (1). Mor-
phological correlates for these neurological deficits are
sclerosis and hyalinosis of small cerebral arteries and
arterioles which are associated with diffuse periventric-
ular white matter abnormalities and central lacunes
demonstrable in computed or magnetic resonance to-
Fig. 1 A. Typical cerebral arterial vessel with hyalinosis and
thickening of the media (arrow) from a patient who suffered
from subcortical vascular encephalopathy (cerebral microan-
gopathy). B. MRT-image from a patient with subcortical vas-
cular encephalopathy showing white matter lesions (arrow).
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mography (Figure 1) (1, 2). Numerous studies have
demonstrated elevated homocysteine concentrations in
plasma as a risk factor for atherosclerosis of the coro-
nary (3, 4), peripheral (5) and cerebral blood vessels
(6–9). Until now, no study has compared homocysteine
plasma concentrations in cerebral macroangiopathy
(large-vessel disease) and cerebral microangiopathy
(small-vessel disease) associated with SVE. Therefore
the aim of the present study was to investigate whether
patients with distinct forms of cerebrovascular disease
differ in their homocysteine concentrations in plasma.
Patients and Methods
Patients and control subjects
In all patients and healthy control subjects, history, clinical ex-
amination, extracranial and transcranial doppler, extracranial
colour Doppler flow imaging and computed tomography (CT)
or magnetic resonance imaging (MRI) were used to classify
cerebrovascular disease. In 82 patients (37 females, 45 males;
median age 73 years) from our clinic, SVE was diagnosed by
combined information from standardized neurological, neu-
ropsychological tests (including the Mini-Mental-State Exami-
nation (MMSE)) in all patients, and further assessments such
as the Structured Interview for the Diagnosis of Dementia
(SIDAM), Brief Assessment Interview (BAI) or Nuremberg Ag-
ing Inventory (NAI) in the majority of participants). Neuroradi-
ological (CT or MRT) examination was performed according to
the ICD-10 criteria (10). Symptoms such as typical gait disor-
ders, urinary incontinence, or emotional disturbances were
used to strengthen the diagnosis. This group was further di-
vided into patients who suffered only from SVE (n=51) and pa-
tients with combined SVE and large-vessel disease (n=31). Ad-
ditionally, 144 patients (55 females, 89 males; median age 67
years) with cerebral large-vessel disease (plaques or stenoses
of the extracranial arteries and increase of cerebral blood flow
velocity to ≥140 cm/s in the large intracranial vessels or both)
were studied. Controls were 102 people (54 females, 48 males;
median age 65 years) without any cerebrovascular disease.
Laboratory analysis
Homocysteine and vitamin B6 were measured in EDTA-
plasma by high-performance liquid chromatography (HPLC)
with a Merck-Hitachi HPLC system from E. Merck, Darmstadt,
Germany. Reagent kits were purchased from Medchrom, Hei-
delberg and Recipe, Munich, Germany. Folate and vitamin B12
were measured with a microparticle-enzyme immunoassay
on the IMX analyzer from Abbott, Wiesbaden, Germany.
Statistics
Spearman’s correlation, Mann-Whitney U-test with a Bonfer-
roni correction, and logistic regression analysis were used as
statistic calculations.
Results
Homocysteine and vitamins
Significantly higher homocysteine concentrations were
found in patients with SVE compared to controls and to
patients with cerebral macroangiopathy only (Figure 2).
Homocysteine concentrations were high, irrespective of
concomitant cerebral macroangiopathy. Within the
group of patients with SVE, homocysteine concentra-
tions did not significantly differ between subjects with
and without concomitant cerebral macroangiopathy
(Figure 2). Interestingly, patients with only cerebral
macroangiopathy did not exhibit significantly different
homocysteine concentrations compared to control sub-
jects without cerebrovascular disease. Patients with SVE
showed significantly decreased plasma concentrations
of vitamin B6, but not of folate and B12, in comparison
with patients without cerebrovascular disease (Table 1).
Risk factors
Concerning the risk factor profile in our study popula-
tion, hypertension was significantly more frequent in
patients with cerebral microangipathy and in patients
with macroangiopathy, compared to control subjects
without cerebrovascular disease (Figure 3). Smoking
was significantly more frequent in patients with cere-
bral macroangiopathy, but not in those with cerebral
microangiopathy only, compared to subjects without
cerebrovascular disease (Figure 3). The frequency of
diabetes was equally distributed in each risk factor
group (Figure 3).
Tab. 1 Plasma concentrations of vitamins in the studies pa-
tients.
Group n B6 (nmol/l) B12 (pmol/l) Folate (nmol/l)
1 102 62.2±57.6 333±199 14.6±6.35
2 144 61.3±65.8 269±109 13.0±5.90
3 31 35.9±16.7* 272±181 13.2±6.71
4 51 43.3±22.9* 275±160 14.7±7.83
Group 1, no cerebrovascular disease; Group 2, cerebral
macroangiopathy; Group 3, cerebral micro-and macroan-
giopathy; Group 4, cerebral microangiopathy. Values are give
as mean±SD. * Significant after Bonferroni correction com-
pared with people without cerebrovascular disease. p<0.05.
Fig. 2 Plasma levels of homocysteine (mean + SD) in the
studied patients. Group 1, no cerebrovascular disease
(n=102); Group 2, cerebral macroangiopathy (n=144); Group
3, cerebral micro-and macroangiopathy (n=31); Group 4 cere-
bral microangiopathy (n=51). * Significant after Bonferroni
correction compared with people without cerebrovascular
disease. p<0.05.
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Using logistic regression analysis with hyperhomo-
cysteinemia, hypertension, age, smoking, and dia-
betes as variables, it could be demonstrated that hy-
perhomocysteinemia (≥15 µmol/l as used in earlier
studies) is associated with the highest risk for SVE
(odds ratio 5.7, p<0.0001, 95% CI 2.5–12.9) followed by
hypertension (5.2, p<0.0001, 95% CI 2.2–12.9), age
(1.1, p<0.001, 95% CI 1.0–1.1) and smoking (3.4,
p<0.05, 95% CI 1.3–9.2).
Discussion
Our study demonstrated that homocysteine concentra-
tion in the peripheral circulation is increased in patients
with cerebral small-vessel disease, but not in those
who suffer only from large-vessel disease as focused
on in previous studies. This suggests that homocys-
teine injures the small penetrating cerebral arteries and
arterioles rather than larger brain-supplying arteries.
As thickening and hyalinosis of the media are impor-
tant features of cerebral small vessel disease, homo-
cysteine may be involved in the pathological activation
of vascular smooth muscle and endothelial cells as has
been shown in vitro (11–15).
Interestingly, logistic regression analysis showed
that hyperhomocysteinemia is an independent risk fac-
tor for SVE that is even stronger than other vascular
risk factors for SVE, e.g. hypertension and diabetes
mellitus. Our findings are in accordance with previous
reports on hyperhomocysteinemia in geriatric patients
with psychiatric disorders (16, for review see 17), some
of whom could have suffered from undiagnosed SVE,
and in patients with diabetes mellitus (18) with mi-
croangiopathic complications. The association be-
tween smoking and SVE can be explained by the fact
that smoking was frequently found in the subgroup of
SVE patients with concomitant large-vessel disease.
The frequency of smokers was not increased in pa-
tients who suffered from SVE without concomitant
large vessel disease. This argues against a role for
smoking as an important risk factor for SVE, but for a
relationship between smoking and large-vessel dis-
ease which has been shown in numerous studies. As
vitamins are involved in key positions in homocysteine
metabolism (19) and as we found significantly lower
homocysteine concentrations in our study population,
it might be suggested that hypovitaminosis could have
contributed to the development of SVE. Interestingly,
we found that especially vitamin B6 plasma levels were
significantly lower in the group of patients suffering
from SVE or SVE in combination with large-vessel dis-
ease. The role of vitamin B6 in hyperhomocysteinemia
is still under discussion but recently published studies
showed that vitamin B6 may have an influence on ho-
mocysteine plasma levels especially in combination
with folate (20, 21). Also, animal studies indicate that
vitamin B6 deficiency is associated with higher homo-
cysteine plasma concentrations and vascular disease
(22). This possible important role of vitamin B6 in ho-
mocysteine metabolism is at least in part supported by
the results of our study.
Because cerebral microangiopathy and macroan-
giopathy can occur together, inclusion of patients with
undiagnosed small-vessel disease in populations with
carotid artery disease (large-vessel disease) might
have resulted in artificially raised mean homocysteine
concentrations in patients with large-vessel disease in
earlier studies (6). This underscores the need to clas-
sify stroke syndromes and to identify patients with
cerebral microangiopathy by exact neurological, neu-
ropsychological, and brain imaging studies in future
studies on hyperhomocysteinemia and cerebrovascu-
lar disease.
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